28 August 2018
Visiongain’s new report Global Graft versus Host Disease (GVHD) Market 2017-2027: Acute, Chronic and Prophylaxis GVHD indicates that the global graft vs host disease market will see $0.51bn in spending in 2021.
The global graft versus host disease market is expected to grow at a CAGR of 7% from 2016-2021 and CAGR of 3% from 2021-2027. The market is expected to grow at a CAGR of 6% from 2016 to 2027. The market is estimated at $0.36bn in 2016, $0.51bn in 2021, and $0.64bn in 2026.
The lead analyst of the report said: “The multibillion-dollar market for therapies to treat Graft versus Host Disease (GVHD) is dominated by Cyclosporine (calcineurin inhibitors), Rapamune (sirolimus), Rituxan/MabThera (rituximab) and Lemtrada (alemtuzumab) which together held a total market share of 52%. The methylpredinisolones and calcineurin inhibitors are mainly entrenched as first line biological agents for GVHD and will continue to lead the market.
The growth of the GVHD market through the forecast period will be driven by recently launched and emerging monoclonal antibodies with alternative mechanisms of action that will compete for patients who respond inadequately to the older treatments.
During the second half of the forecast period, however, the use of novel cell based therapies may become more prevalent in biologic-naive patients, depending on each agent showing an acceptable safety profile and physicians gaining confidence in their ability to protect against GVHD infections.”
The 162-page report contains 62 tables and 76 figures that add visual analysis in order to explain the developing trends within the Global Graft versus Host Disease market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments by treatment type of this market: acute GVHD, Chronic GVHD and Prophylaxis GVHD. The report also provides forecasts for the leading drugs in the GVHD market. The 162-page report offers market forecasts for the United States (US), Germany, France, the UK, Italy, Spain and Japan, segmented by treatment type and product.
Moreover, the report provides GVHD patient number forecast to 2027 per leading country, segmented into total allogenic cases, first allogenic cases, acute GVHD and chronic GVHD
The report Global Graft versus Host Disease (GVHD) Market 2017-2027: Acute, Chronic and Prophylaxis GVHD report will be of value to anyone who wants to better understand the graft vs host disease market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the graft versus host disease market.
Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
About visiongain Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market for ophthalmic drugs is a growing one.
17 June 2019
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.
06 June 2019
Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.